Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Depomed’s Gabapentin GR Fails Phase III Postherpetic Neuralgia Study

This article was originally published in The Pink Sheet Daily

Executive Summary

Outcome is not expected to affect product’s ongoing clinical development for menopausal hot flashes.

You may also be interested in...



Depomed Revises Protocol For Gabapentin GR Postherpetic Neuralgia Phase III

After the initial Phase III trial of the extended-release drug failed to show a benefit over placebo in PHN, Depomed gives it another go.

Depomed Revises Protocol For Gabapentin GR Postherpetic Neuralgia Phase III

After the initial Phase III trial of the extended-release drug failed to show a benefit over placebo in PHN, Depomed gives it another go.

NeurogesX Reports Successful Phase III Trial For NGX-4010 In Post-Herpetic Neuralgia

Firm plans to file with EMEA for peripheral neuropathic pain indication later this year.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066292

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel